Catalyst Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Gyre Therapeutics

15/08/2022 22:02

* Catalyst Biosciences Inc  CBIO.OQ  reported quarterly
adjusted
earnings of $1.64​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 24 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * The mean earnings estimate of analysts had risen by
about 19.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Catalyst Biosciences Inc shares had risen by 7.9% this
quarter and gained 110.1% so far this year.
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.24          1.64           Beat
 Mar. 31 2022      -0.44          -0.46          Missed
 Dec. 31 2021      -0.59          -0.64          Missed
 Sep. 30 2021      -0.66          -0.80          Missed